June 2 new date for WntResearch Annual General Meeting

The Board of Directors has decided to postpone the date of the Annual General Meeting to Thursday, June 2, taking into account that Pernilla Sandwall by then has acted as the new CEO for a period and has had the opportunity to get further understanding of the business.

The Annual General Meeting will be conducted with a postal voting procedure. On the same day, a digital meeting will be arranged in which Pernilla Sandwall will convey her views on the way forward for WntResearch.

For further information:

Gudrun Anstrén, Acting CEO, WntResearch AB
e-post: ga@wntreseacrh.com

About WntResearch

WntResearch is a biotech company in oncology that develops new therapies intended to prevent the metastatic process. The company's research is focused on studying the endogenous protein WNT5A, which in scientific studies has shown to affect tumor cells' ability to move and spread in the body. WntResearch drug candidate Foxy-5 is a peptide that mimics the function of WNT5A and is intended to reduce the mobility and spread of cancer cells thus preventing metastases from occurring. Although current cancer treatment has become more effective, there are no effective ways to prevent the onset of metastases that cause about 90 percent of all cancer-related deaths. Foxy-5 has a unique mechanism of action and has shown a good safety profile with few side effects in two Phase I clinical trials. The safety and efficacy of Foxy-5 are now being evaluated in the ongoing Phase 2 clinical trial NeoFox, in patients with stage II-III colon cancer.

WntResearch is listed on the Spotlight Stock Market. For more information, please visit: www.wntresearch.com